Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Paul Sondel

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Physiology

Anatomy

Living Beings

Mice

Disorders

Procedures

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
89
Hank, Jacquelyn
29
Albertini, Mark
23
Rakhmilevich, Alexander
19
Gan, Jacek
19
Sosman, Jeffrey
15
Mahvi, David
13
Gillies, Stephen
12
Buhtoiarov, Ilia
12
Surfus, Jean
10
Trigg, ME
10
Schiller, Joan
9
Yang, Ning-Sun
8
Reisfeld, Ralph
7
Lindstrom, Mary
6
Lum, Hillary

Sign-in to see all Coauthors

Publications

TOP 3
Hank Jacquelyn A; Gan Jacek; Ryu Hyunji; Ostendorf Amy; Stauder Michael C; Sternberg Adam; Albertini Mark; Lo Kin-Ming; Gillies Stephen D; Eickhoff Jens; Sondel Paul M
Immunogenicity of the hu14.18-IL2 immunocytokine molecule in adults with melanoma and children with neuroblastoma.
Johnson Erik E; Yamane Brett H; Buhtoiarov Ilia N; Lum Hillary D; Rakhmilevich Alexander L; Mahvi David M; Gillies Stephen D; Sondel Paul M
Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma.
Yamane Brett H; Hank Jacquelyn A; Albertini Mark R; Sondel Paul M
The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Paul Sondel (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Hank Jacquelyn A; Gan Jacek; Ryu Hyunji; Ostendorf Amy; Stauder Michael C; Sternberg Adam; Albertini Mark; Lo Kin-Ming; Gillies Stephen D; Eickhoff Jens; Sondel Paul M
Immunogenicity of the hu14.18-IL2 immunocytokine molecule in adults with melanoma and children with neuroblastoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(18):5923-30.
2009: Johnson Erik E; Yamane Brett H; Buhtoiarov Ilia N; Lum Hillary D; Rakhmilevich Alexander L; Mahvi David M; Gillies Stephen D; Sondel Paul M
Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(15):4875-84.
2009: Yamane Brett H; Hank Jacquelyn A; Albertini Mark R; Sondel Paul M
The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma.
Expert opinion on investigational drugs 2009;18(7):991-1000.
2009: Wu Qing-Li; Buhtoiarov Ilia N; Sondel Paul M; Rakhmilevich Alexander L; Ranheim Erik A
Tumoricidal effects of activated macrophages in a mouse model of chronic lymphocytic leukemia.
Journal of immunology (Baltimore, Md. : 1950) 2009;182(11):6771-8.
2009: Capitini Christian M; Cooper Laurence J N; Egeler R Maarten; Handgretinger Rupert; Locatelli Franco; Sondel Paul M; Mackall Crystal L
Highlights of the First International "Immunotherapy in Pediatric Oncology: Progress and Challenges" Meeting.
Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology 2009;31(4):227-44.
2009: Buhtoiarov Ilia N; Rakhmilevich Alexander L; Lanier Lewis L; Ranheim Erik A; Sondel Paul M
Naive mouse macrophages become activated following recognition of L5178Y lymphoma cells via concurrent ligation of CD40, NKG2D, and CD18 molecules.
Journal of immunology (Baltimore, Md. : 1950) 2009;182(4):1940-53.
2009: Gilman Andrew L; Ozkaynak M Fevzi; Matthay Katherine K; Krailo Mark; Yu Alice L; Gan Jacek; Sternberg Adam; Hank Jacquelyn A; Seeger Robert; Reaman Gregory H; Sondel Paul M
Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(1):85-91.
2008: Johnson Erik E; Lum Hillary D; Rakhmilevich Alexander L; Schmidt Brian E; Furlong Meghan; Buhtoiarov Ilia N; Hank Jacquelyn A; Raubitschek Andrew; Colcher David; Reisfeld Ralph A; Gillies Stephen D; Sondel Paul M
Intratumoral immunocytokine treatment results in enhanced antitumor effects.
Cancer immunology, immunotherapy : CII 2008;57(12):1891-902.
2008: Meany Holly J; Seibel Nita L; Sun Junfeng; Finklestein Jerry Z; Sato Judith; Kelleher John; Sondel Paul; Reaman Gregory
Phase 2 trial of recombinant tumor necrosis factor-alpha in combination with dactinomycin in children with recurrent Wilms tumor.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2008;31(7):679-83.
2008: Rakhmilevich Alexander L; Buhtoiarov Ilia N; Malkovsky Miroslav; Sondel Paul M
CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors.
Cancer immunology, immunotherapy : CII 2008;57(8):1151-60.
2008: Grupp Stephan A; Verneris Michael; Sondel Paul M; Cooper Laurence J N
Immunotherapy for pediatric cancer.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2008;14(1 Suppl 1):33-43.
2007: Neal Zane C; Sondel Paul M; Bates Mary Kay; Gillies Stephen D; Herweijer Hans
Flt3-L gene therapy enhances immunocytokine-mediated antitumor effects and induces long-term memory.
Cancer immunology, immunotherapy : CII 2007;56(11):1765-74.
2007: Mahvi D M; Henry M B; Albertini M R; Weber S; Meredith K; Schalch H; Rakhmilevich A; Hank J; Sondel P
Intratumoral injection of IL-12 plasmid DNA--results of a phase I/IB clinical trial.
Cancer gene therapy 2007;14(8):717-23.
2007: Peshes-Yaloz Naama; Rosen Dalia; Sondel Paul M; Krammer Peter H; Berke Gideon
Up-regulation of Fas (CD95) expression in tumour cells in vivo.
Immunology 2007;120(4):502-11.
2007: Buhtoiarov Ilia N; Sondel Paul M; Eickhoff Jens C; Rakhmilevich Alexander L
Macrophages are essential for antitumour effects against weakly immunogenic murine tumours induced by class B CpG-oligodeoxynucleotides.
Immunology 2007;120(3):412-23.
2007: Cassaday Ryan D; Sondel Paul M; King David M; Macklin Michael D; Gan Jacek; Warner Tom F; Zuleger Cindy L; Bridges Alan J; Schalch Heidi G; Kim Kyung Mann; Hank Jacquelyn A; Mahvi David M; Albertini Mark R
A phase I study of immunization using particle-mediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(2 Pt 1):540-9.
2007: Johnson Erik; Dean Shannon M; Sondel Paul M
Antibody-based immunotherapy in high-risk neuroblastoma.
Expert reviews in molecular medicine 2007;9(34):1-21.
2006: Choi Brian S; Sondel Paul M; Hank Jacquelyn A; Schalch Heidi; Gan Jacek; King David M; Kendra Kari; Mahvi David; Lee Li-Yin; Kim Kyungmann; Albertini Mark R
Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma.
Cancer immunology, immunotherapy : CII 2006;55(7):761-74.
2006: Lum Hillary D; Buhtoiarov Ilia N; Schmidt Brian E; Berke Gideon; Paulnock Donna M; Sondel Paul M; Rakhmilevich Alexander L
Tumoristatic effects of anti-CD40 mAb-activated macrophages involve nitric oxide and tumour necrosis factor-alpha.
Immunology 2006;118(2):261-70.
2006: Lum Hillary D; Buhtoiarov Ilia N; Schmidt Brian E; Berke Gideon; Paulnock Donna M; Sondel Paul M; Rakhmilevich Alexander L
In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages.
Journal of leukocyte biology 2006;79(6):1181-92.
2006: Osenga Kaci L; Hank Jacquelyn A; Albertini Mark R; Gan Jacek; Sternberg Adam G; Eickhoff Jens; Seeger Robert C; Matthay Katherine K; Reynolds C Patrick; Twist Clare; Krailo Mark; Adamson Peter C; Reisfeld Ralph A; Gillies Stephen D; Sondel Paul M;
A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(6):1750-9.
2006: Buhtoiarov Ilia N; Lum Hillary D; Berke Gideon; Sondel Paul M; Rakhmilevich Alexander L
Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects.
Journal of immunology (Baltimore, Md. : 1950) 2006;176(1):309-18.
2005: Buhtoiarov Ilia N; Lum Hillary; Berke Gideon; Paulnock Donna M; Sondel Paul M; Rakhmilevich Alexander L
CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro.
Journal of immunology (Baltimore, Md. : 1950) 2005;174(10):6013-22.
2005: Albertini Mark R; Hank Jacquelyn A; Sondel Paul M
Native and genetically engineered anti-disialoganglioside monoclonal antibody treatment of melanoma.
Cancer chemotherapy and biological response modifiers 2005;22():789-97.
2004: Weber Sharon M; Qi Chen; Neal Zane; Sondel Paul; Mahvi David M
IL-12 cDNA direct injection: antimetastatic effect from a single injection in a murine hepatic metastases model.
The Journal of surgical research 2004;122(2):210-7.
2004: King David M; Albertini Mark R; Schalch Heidi; Hank Jacquelyn A; Gan Jacek; Surfus Jean; Mahvi David; Schiller Joan H; Warner Thomas; Kim KyungMann; Eickhoff Jens; Kendra Kari; Reisfeld Ralph; Gillies Stephen D; Sondel Paul
Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(22):4463-73.
2004: Rakhmilevich Alexander L; Hooper Andrea T; Hicklin Daniel J; Sondel Paul M
Treatment of experimental breast cancer using interleukin-12 gene therapy combined with anti-vascular endothelial growth factor receptor-2 antibody.
Molecular cancer therapeutics 2004;3(8):969-76.
2004: Neal Zane C; Yang Jeannie C; Rakhmilevich Alexander L; Buhtoiarov Ilia N; Lum Hillary E; Imboden Michael; Hank Jacquelyn A; Lode Holger N; Reisfeld Ralph A; Gillies Stephen D; Sondel Paul M
Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(14):4839-47.
2004: Connor Joseph P; Felder Mildred; Hank Jacquelyn; Harter Josephine; Gan Jacek; Gillies Stephen D; Sondel Paul
Ex vivo evaluation of anti-EpCAM immunocytokine huKS-IL2 in ovarian cancer.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2004;27(3):211-9.
2004: Neal Zane C; Imboden Michael; Rakhmilevich Alexander L; Kim Kyung-Mann; Hank Jacquelyn A; Surfus Jean; Dixon John R; Lode Holger N; Reisfeld Ralph A; Gillies Stephen D; Sondel Paul M
NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy.
Cancer immunology, immunotherapy : CII 2004;53(1):41-52.
2003: Imboden Michael; Shi Fushun; Pugh Thomas D; Freud Aharon G; Thom Nathaniel J; Hank Jacquelin A; Hao Zhengling; Staelin Stephen T; Sondel Paul M; Mahvi David M
Safety of interleukin-12 gene therapy against cancer: a murine biodistribution and toxicity study.
Human gene therapy 2003;14(11):1037-48.
2003: Sondel Paul M; Buhtoiarov Ilia N; DeSantes Kenneth
Pleasant memories: remembering immune protection while forgetting about graft-versus-host disease.
The Journal of clinical investigation 2003;112(1):25-7.
2003: Sondel Paul M; Hank Jacquelyn A; Gan Jacek; Neal Zane; Albertini Mark R
Preclinical and clinical development of immunocytokines.
Current opinion in investigational drugs (London, England : 2000) 2003;4(6):696-700.
2003: Hank Jacquelyn A; Surfus Jean E; Gan Jacek; Ostendorf Amy; Gillies Stephen D; Sondel Paul M
Determination of peak serum levels and immune response to the humanized anti-ganglioside antibody-interleukin-2 immunocytokine.
Methods in molecular medicine 2003;85():123-31.
2002: Shi Fushun; Rakhmilevich Alexander L; Heise Chuck P; Oshikawa Katsuhisa; Sondel Paul M; Yang Ning-Sun; Mahvi David M
Intratumoral injection of interleukin-12 plasmid DNA, either naked or in complex with cationic lipid, results in similar tumor regression in a murine model.
Molecular cancer therapeutics 2002;1(11):949-57.
2002: Mahvi D M; Shi F-S; Yang N-S; Weber S; Hank J; Albertini M; Schiller J; Schalch H; Larson M; Pharo L; Gan J; Heisey D; Warner T; Sondel P M
Immunization by particle-mediated transfer of the granulocyte-macrophage colony-stimulating factor gene into autologous tumor cells in melanoma or sarcoma patients: report of a phase I/IB study.
Human gene therapy 2002;13(14):1711-21.
2002: Li Jie-Hui; Rosen Dalia; Sondel Paul; Berke Gideon
Immune privilege and FasL: two ways to inactivate effector cytotoxic T lymphocytes by FasL-expressing cells.
Immunology 2002;105(3):267-77.
2001: Dinndorf P; Krailo M; Liu-Mares W; Frierdich S; Sondel P; Reaman G
Phase I trial of anti-B4-blocked ricin in pediatric patients with leukemia and lymphoma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2001;24(6):511-6.
2001: Sondel P M; Hank J A
Antibody-directed, effector cell-mediated tumor destruction.
Hematology/oncology clinics of North America 2001;15(4):703-21.
2001: Rakhmilevich A L; Imboden M; Hao Z; Macklin M D; Roberts T; Wright K M; Albertini M R; Yang N S; Sondel P M
Effective particle-mediated vaccination against mouse melanoma by coadministration of plasmid DNA encoding Gp100 and granulocyte-macrophage colony-stimulating factor.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(4):952-61.
2001: Monson N L; Fenske T J; Wei S; Okragly A J; de Jong J L; Haak-Frendscho M; O'Shea J; Djeu J; Sondel P M
A p74 common gamma receptor chain isoform facilitates IL-2 and IL-15 responses by the myelomonocytic cell line Tf-1beta2.
Journal of leukocyte biology 2001;69(3):419-25.
2001: Imboden M; Murphy K R; Rakhmilevich A L; Neal Z C; Xiang R; Reisfeld R A; Gillies S D; Sondel P M
The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy.
Cancer research 2001;61(4):1500-7.
2001: Eastman M E; Khorsand M; Maki D G; Williams E C; Kim K; Sondel P M; Schiller J H; Albertini M R
Central venous device-related infection and thrombosis in patients treated with moderate dose continuous-infusion interleukin-2.
Cancer 2001;91(4):806-14.
2001: Oshikawa K; Rakhmilevich A L; Shi F; Sondel P M; Yang N; Mahvi D M
Interleukin 12 gene transfer into skin distant from the tumor site elicits antimetastatic effects equivalent to local gene transfer.
Human gene therapy 2001;12(2):149-60.
2001: Turner J G; Rakhmilevich A L; Burdelya L; Neal Z; Imboden M; Sondel P M; Yu H
Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK cells.
Journal of immunology (Baltimore, Md. : 1950) 2001;166(1):89-94.
2000: Ozkaynak M F; Sondel P M; Krailo M D; Gan J; Javorsky B; Reisfeld R A; Matthay K K; Reaman G H; Seeger R C
Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(24):4077-85.
2000: Rakhmilevich A L; Janssen K; Hao Z; Sondel P M; Yang N S
Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism.
Cancer gene therapy 2000;7(6):826-38.
2000: Hotton K M; Khorsand M; Hank J A; Albertini M; Kim K M; Wilding G; Salamat M S; Larson M; Sondel P; Schiller J H
A phase Ib/II trial of granulocyte-macrophage-colony stimulating factor and interleukin-2 for renal cell carcinoma patients with pulmonary metastases: a case of fatal central nervous system thrombosis.
Cancer 2000;88(8):1892-901.
2000: Sievers E L; Lange B J; Sondel P M; Krailo M D; Gan J; Tjoa T; Liu-Mares W; Feig S A
Children's cancer group trials of interleukin-2 therapy to prevent relapse of acute myelogenous leukemia.
The cancer journal from Scientific American 2000;6 Suppl 1():S39-44.
1999: Oshikawa K; Shi F; Rakhmilevich A L; Sondel P M; Mahvi D M; Yang N S
Synergistic inhibition of tumor growth in a murine mammary adenocarcinoma model by combinational gene therapy using IL-12, pro-IL-18, and IL-1beta converting enzyme cDNA.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(23):13351-6.
1999: Soergel S A; MacEwen E G; Vail D M; Potter D M; Sondel P M; Helfand S C
The immunotherapeutic potential of activated canine alveolar macrophages and antitumor monoclonal antibodies in metastatic canine melanoma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1999;22(5):443-53.
1999: Kendra K; Gan J; Ricci M; Surfus J; Shaker A; Super M; Frost J D; Rakhmilevich A; Hank J A; Gillies S D; Sondel P M
Pharmacokinetics and stability of the ch14.18-interleukin-2 fusion protein in mice.
Cancer immunology, immunotherapy : CII 1999;48(5):219-29.
1999: Gan J; Kendra K; Ricci M; Hank J A; Gillies S D; Sondel P M
Specific enzyme-linked immunosorbent assays for quantitation of antibody-cytokine fusion proteins.
Clinical and diagnostic laboratory immunology 1999;6(2):236-42.
1999: Hank J A; Surfus J; Gan J; Albertini M; Lindstrom M; Schiller J H; Hotton K M; Khorsand M; Sondel P M
Distinct clinical and laboratory activity of two recombinant interleukin-2 preparations.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(2):281-9.
1999: Hank J A; Albertini M R; Sondel P M
Monoclonal antibodies, cytokines and fusion proteins in the treatment of malignant disease.
Cancer chemotherapy and biological response modifiers 1999;18():210-22.
1998: de Jong J L; Farner N L; Sondel P M
Distinctions in lymphocyte responses to IL-2 and IL-15 reflect differential ligand binding interactions with the IL-2Rbeta chain and suggest differential roles for the IL-2Ralpha and IL-15Ralpha subunits.
Cytokine 1998;10(12):920-30.
1998: Nicolet C M; Surfus J M; Hank J A; Sondel P M
Transcription factor activation in lymphokine activated killer cells and lymphocytes from patients receiving IL-2 immunotherapy.
Cancer immunology, immunotherapy : CII 1998;46(6):327-37.
1998: de Jong J L; Farner N L; Javorsky B R; Lindstrom M J; Hank J A; Sondel P M
Differential quantitative effects of interleukin (IL)-2 and IL-15 on cytotoxic activity and proliferation by lymphocytes from patients receiving in vivo IL-2 therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(5):1287-96.
1998: Sievers E L; Lange B J; Sondel P M; Krailo M D; Gan J; Liu-Mares W; Feig S A
Feasibility, toxicity, and biologic response of interleukin-2 after consolidation chemotherapy for acute myelogenous leukemia: a report from the Children's Cancer Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(3):914-9.
1997: Sondel P M; Hank J A
Combination therapy with interleukin-2 and antitumor monoclonal antibodies.
The cancer journal from Scientific American 1997;3 Suppl 1():S121-7.
1997: Albertini M R; Hank J A; Schiller J H; Khorsand M; Borchert A A; Gan J; Bechhofer R; Storer B; Reisfeld R A; Sondel P M
Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(8):1277-88.
1997: Frost J D; Hank J A; Reaman G H; Frierdich S; Seeger R C; Gan J; Anderson P M; Ettinger L J; Cairo M S; Blazar B R; Krailo M D; Matthay K K; Reisfeld R A; Sondel P M
A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group.
Cancer 1997;80(2):317-33.
1997: Farner N L; Gan J; de Jong J L; Leary T P; Fenske T S; Buckley P; Dunlap S; Sondel P M
Alteration of the CD34+ Tf-1 beta cell line profile in response to long-term exposure to IL-15.
Cytokine 1997;9(5):316-27.
1997: Mahvi D M; Sondel P M; Yang N S; Albertini M R; Schiller J H; Hank J; Heiner J; Gan J; Swain W; Logrono R
Phase I/IB study of immunization with autologous tumor cells transfected with the GM-CSF gene by particle-mediated transfer in patients with melanoma or sarcoma.
Human gene therapy 1997;8(7):875-91.
1997: Nicolet C M; Siegel D H; Surfus J E; Sondel P M
TAG-72-reactive antibody CC49 recognizes molecules expressed by hematopoietic cell lines.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 1997;18(6):356-66.
1996: Hank J A; Surfus J E; Gan J; Jaeger P; Gillies S D; Reisfeld R A; Sondel P M
Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2).
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(12):1951-9.
1996: Mahvi D M; Burkholder J K; Turner J; Culp J; Malter J S; Sondel P M; Yang N S
Particle-mediated gene transfer of granulocyte-macrophage colony-stimulating factor cDNA to tumor cells: implications for a clinically relevant tumor vaccine.
Human gene therapy 1996;7(13):1535-43.
1996: Albertini M R; Gan J; Jaeger P; Hank J A; Storer B; Schell K; Rivest T; Surfus J; Reisfeld R A; Schiller J H; Sondel P M
Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanoma.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1996;19(4):278-95.
1996: Rakhmilevich A L; Turner J; Ford M J; McCabe D; Sun W H; Sondel P M; Grota K; Yang N S
Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(13):6291-6.
1996: Surfus J E; Hank J A; Oosterwijk E; Welt S; Lindstrom M J; Albertini M R; Schiller J H; Sondel P M
Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1996;19(3):184-91.
1996: Schiller J H; Hank J A; Khorsand M; Storer B; Borchert A; Huseby-Moore K; Burns D; Wesly O; Albertini M R; Wilding G; Sondel P M
Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(2):319-30.
1996: de Jong J L; Farner N L; Widmer M B; Giri J G; Sondel P M
Interaction of IL-15 with the shared IL-2 receptor beta and gamma c subunits. The IL-15/beta/gamma c receptor-ligand complex is less stable than the IL-2/beta/gamma c receptor-ligand complex.
Journal of immunology (Baltimore, Md. : 1950) 1996;156(4):1339-48.
1996: Helfand S C; Hank J A; Gan J; Sondel P M
Lysis of human tumor cell lines by canine complement plus monoclonal antiganglioside antibodies or natural canine xenoantibodies.
Cellular immunology 1996;167(1):99-107.
1995: Farner N L; Voss S D; Leary T P; Gan J; Hakimi J; Evans G; Ju G; Sondel P M
Distinction between gamma c detection and function in YT lymphoid cells and in the granulocyte-macrophage colony-stimulating factor-responsive human myeloid cell line, Tf-1.
Blood 1995;86(12):4568-78.
1995: Farner N L; Voss S D; Sondel P M
X-linked severe combined immunodeficiency disease and the gamma c receptor component: prospects for molecular diagnosis.
Clinical and diagnostic laboratory immunology 1995;2(5):518-23.
1995: Nicolet C M; Burkholder J K; Gan J; Culp J; Kashmiri S V; Schlom J; Yang N S; Sondel P M
Expression of a tumor-reactive antibody-interleukin 2 fusion protein after in vivo particle-mediated gene delivery.
Cancer gene therapy 1995;2(3):161-70.
1995: Helfand S C; Modiano J F; Moore P F; Soergel S A; MacWilliams P S; Dubielzig R D; Hank J A; Gelfand E W; Sondel P M
Functional interleukin-2 receptors are expressed on natural killer-like leukemic cells from a dog with cutaneous lymphoma.
Blood 1995;86(2):636-45.
1995: Mahvi D M; Madsen J A; Witt P L; Sondel P M
Interferon alpha enhances expression of TAG-72 and carcinoembryonic antigen in patients with primary colorectal cancer.
Cancer immunology, immunotherapy : CII 1995;40(5):311-4.
1994: Helfand S C; Soergel S A; Donner R L; Gan J; Hank J A; Lindstrom M J; Sondel P M
Potential to involve multiple effector cells with human recombinant interleukin-2 and antiganglioside monoclonal antibodies in a canine malignant melanoma immunotherapy model.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1994;16(3):188-97.
1994: Helfand S C; Soergel S A; MacWilliams P S; Hank J A; Sondel P M
Clinical and immunological effects of human recombinant interleukin-2 given by repetitive weekly infusion to normal dogs.
Cancer immunology, immunotherapy : CII 1994;39(2):84-92.
1994: Kaur I; de Jong J; Schell K; Hank J; Fisch P; Sondel P M
Human peripheral gamma delta T cells are stimulated by Daudi Burkitt's lymphoma and not by any other Burkitt's lymphoma tested.
Cellular immunology 1994;156(1):54-61.
1994: Oettel K R; Wesly O H; Albertini M R; Hank J A; Iliopolis O; Sosman J A; Voelkerding K; Wu S Q; Clark S S; Sondel P M
Allogeneic T-cell clones able to selectively destroy Philadelphia chromosome-bearing (Ph1+) human leukemia lines can also recognize Ph1- cells from the same patient.
Blood 1994;83(11):3390-402.
1994: Voss S D; Hong R; Sondel P M
Severe combined immunodeficiency, interleukin-2 (IL-2), and the IL-2 receptor: experiments of nature continue to point the way.
Blood 1994;83(3):626-35.
1994: Frost J D; Sondel P M
Immunotherapy for infection and malignancy in children with cancer.
Advances in pediatrics 1994;41():385-413.
1994: Helfand S C; Soergel S A; Modiano J F; Hank J A; Sondel P M
Induction of lymphokine-activated killer (LAK) activity in canine lymphocytes with low dose human recombinant interleukin-2 in vitro.
Cancer biotherapy 1994;9(3):237-44.
1993: Hank J A; Albertini M R; Schiller J; Sondel P M
Activation of multiple effector mechanisms to enhance tumor immunotherapy.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;14(4):329-35.
1993: Mahvi D M; Carper S W; Storm F K; Teal S R; Sondel P M
Overexpression of 27-kDa heat-shock protein in MCF-7 breast cancer cells: effects on lymphocyte-mediated killing by natural killer and gamma delta T cells.
Cancer immunology, immunotherapy : CII 1993;37(3):181-6.
1993: Sondel P M
Biologic and immunologic approaches to comprehensive therapy for pediatric malignant conditions. Laboratory-clinical interaction.
Cancer 1993;71(10 Suppl):3429-34.
1993: Albertini M R; Howard S P; Fisch P; Lindstrom M J; Hank J A; Gould M N; Sondel P M
Modulation of target-cell culture conditions alters susceptibility to lymphocyte-mediated lysis.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;13(4):243-51.
1993: Kaur I; Voss S D; Gupta R S; Schell K; Fisch P; Sondel P M
Human peripheral gamma delta T cells recognize hsp60 molecules on Daudi Burkitt's lymphoma cells.
Journal of immunology (Baltimore, Md. : 1950) 1993;150(5):2046-55.
1993: Voss S D; Leary T P; Sondel P M; Robb R J
Identification of a direct interaction between interleukin 2 and the p64 interleukin 2 receptor gamma chain.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(6):2428-32.
1993: Sondel P M
Introduction: advances in pediatric bone marrow transplantation.
The American journal of pediatric hematology/oncology 1993;15(1):1-2.
1993: Gambacorti-Passerini C; Hank J A; Albertini M R; Borchert A A; Moore K H; Schiller J H; Bechhofer R; Borden E C; Storer B; Sondel P M
A pilot phase II trial of continuous-infusion interleukin-2 followed by lymphokine-activated killer cell therapy and bolus-infusion interleukin-2 in renal cancer.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;13(1):43-8.
1992: Klein B S; Sondel P M; Jones J M
WI-1, a novel 120-kilodalton surface protein on Blastomyces dermatitidis yeast cells, is a target antigen of cell-mediated immunity in human blastomycosis.
Infection and immunity 1992;60(10):4291-300.
1992: Voss S D; Sondel P M; Robb R J
Characterization of the interleukin 2 receptors (IL-2R) expressed on human natural killer cells activated in vivo by IL-2: association of the p64 IL-2R gamma chain with the IL-2R beta chain in functional intermediate-affinity IL-2R.
The Journal of experimental medicine 1992;176(2):531-41.
1992: Fisch P; Oettel K; Fudim N; Surfus J E; Malkovsky M; Sondel P M
MHC-unrestricted cytotoxic and proliferative responses of two distinct human gamma/delta T cell subsets to Daudi cells.
Journal of immunology (Baltimore, Md. : 1950) 1992;148(8):2315-23.
1992: Bogner M P; Voss S D; Bechhofer R; Hank J A; Roper M; Poplack D; Hammond D; Sondel P M
Serum CD25 levels during interleukin-2 therapy: dose dependence and correlations with clinical toxicity and lymphocyte surface sCD25 expression.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1992;11(2):111-8.
1992: Albertini M R; Gibson D F; Robinson S P; Howard S P; Tans K J; Lindstrom M J; Robinson R R; Tormey D C; Jordan V C; Sondel P M
Influence of estradiol and tamoxifen on susceptibility of human breast cancer cell lines to lysis by lymphokine-activated killer cells.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1992;11(1):30-9.
1992: Albertini M R; Hank J A; Sondel P M
Strategies for improving antitumor activity utilizing IL-2: preclinical models and analysis of antitumor activity of lymphocytes from patients receiving IL-2.
Biotherapy (Dordrecht, Netherlands) 1992;4(3):189-98.
1992: Sondel P M; Kawai H; Wesly O H
Harnessing graft versus leukemia: implications for IL-2 treatment.
Bone marrow transplantation 1992;10 Suppl 1():13-5.
1991: Gambacorti-Passerini C; Hank J A; Borchert A; Moore K; Malkovska V; Sondel P
In vivo effects of multiple cycles of recombinant interleukin-2 (IL2) on peripheral granulocyte-macrophage hematopoietic progenitors circulating in the blood of cancer patients.
Tumori 1991;77(5):420-2.
1991: Weil-Hillman G; Schell K; Segal D M; Hank J A; Sosman J A; Sondel P M
Activation of human T cells obtained pre- and post-interleukin-2 (IL-2) therapy by anti-CD3 monoclonal antibody plus IL-2: implications for combined in vivo treatment.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1991;10(4):267-77.
1991: Sondel P M
Interleukin-2: prospects for lymphocyte-mediated destruction of pediatric malignancies.
The Journal of pediatrics 1991;118(3):S14-6.
1991: Cannon A; Hank J A; Sondel P M
BLT-esterase activity following in vitro and in vivo activation of human lymphocytes with interleukin-2. In vivo IL-2 induces BLT-esterase.
Biotherapy (Dordrecht, Netherlands) 1991;3(3):253-60.
1991: Sturm E; Braakman E; Fisch P; Sondel P M; Bolhuis R L
Daudi cell specificity correlates with the use of a V gamma 9-V delta 2 encoded TCR gamma delta.
Current topics in microbiology and immunology 1991;173():183-8.
1991: Fisch P; Kovats S; Fundim N; Sturm E; Braakman E; DeMars R; Bolhuis R L; Sondel P M; Malkovsky M
Function and specificity of human V gamma 9/V delta 2 T lymphocytes.
Current topics in microbiology and immunology 1991;173():179-82.
1991: Albertini M R; Nicklas J A; Chastenay B F; Hunter T C; Albertini R J; Clark S S; Hank J A; Sondel P M
Analysis of T cell receptor beta and gamma genes from peripheral blood, regional lymph node and tumor-infiltrating lymphocyte clones from melanoma patients.
Cancer immunology, immunotherapy : CII 1991;32(5):325-30.
1991: Brown R R; Ozaki Y; Datta S P; Borden E C; Sondel P M; Malone D G
Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS.
Advances in experimental medicine and biology 1991;294():425-35.
1990: Albertini M R; Sosman J A; Hank J A; Moore K H; Borchert A; Schell K; Kohler P C; Bechhofer R; Storer B; Sondel P M
The influence of autologous lymphokine-activated killer cell infusions on the toxicity and antitumor effect of repetitive cycles of interleukin-2.
Cancer 1990;66(12):2457-64.
1990: Sturm E; Braakman E; Fisch P; Vreugdenhil R J; Sondel P; Bolhuis R L
Human V gamma 9-V delta 2 T cell receptor-gamma delta lymphocytes show specificity to Daudi Burkitt's lymphoma cells.
Journal of immunology (Baltimore, Md. : 1950) 1990;145(10):3202-8.
1990: Albertini M R; Oettel K R; Weil-Hillman G; Lindstrom M J; Schell K; Hank J A; Sondel P M
Limiting dilution analysis of lymphokine-activated killer cell precursor frequencies in peripheral blood lymphocytes of cancer patients receiving interleukin-2 therapy.
Journal of biological response modifiers 1990;9(5):456-62.
1990: Voss S D; Robb R J; Weil-Hillman G; Hank J A; Sugamura K; Tsudo M; Sondel P M
Increased expression of the interleukin 2 (IL-2) receptor beta chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL-2 binding.
The Journal of experimental medicine 1990;172(4):1101-14.
1990: Hank J A; Robinson R R; Surfus J; Mueller B M; Reisfeld R A; Cheung N K; Sondel P M
Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2.
Cancer research 1990;50(17):5234-9.
1990: Bolhuis R L; Sturm E; Fisch P; Sondel P M; Braakman E
Human gamma delta T lymphocyte subsets: activation by superantigens?
Research in immunology 1990;141(7):658-63.
1990: Lam V; DeMars R; Chen B P; Hank J A; Kovats S; Fisch P; Sondel P M
Human T cell receptor-gamma delta-expressing T-cell lines recognize MHC-controlled elements on autologous EBV-LCL that are not HLA-A, -B, -C, -DR, -DQ, or -DP.
Journal of immunology (Baltimore, Md. : 1950) 1990;145(1):36-45.
1990: Fisch P; Malkovsky M; Braakman E; Sturm E; Bolhuis R L; Prieve A; Sosman J A; Lam V A; Sondel P M
Gamma/delta T cell clones and natural killer cell clones mediate distinct patterns of non-major histocompatibility complex-restricted cytolysis.
The Journal of experimental medicine 1990;171(5):1567-79.
1990: Sosman J A; Oettel K R; Smith S D; Hank J A; Fisch P; Sondel P M
Specific recognition of human leukemic cells by allogeneic T cells: II. Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated nonleukemic cells.
Blood 1990;75(10):2005-16.
1990: Weil-Hillman G; Voss S D; Fisch P; Schell K; Hank J A; Sosman J A; Sugamura K; Sondel P M
Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype.
Cancer research 1990;50(9):2683-91.
1990: Borden E C; Sondel P M
Lymphokines and cytokines as cancer treatment. Immunotherapy realized.
Cancer 1990;65(3 Suppl):800-14.
1990: Hank J A; Sosman J A; Kohler P C; Bechhofer R; Storer B; Sondel P M
Depressed in vitro T cell responses concomitant with augmented interleukin-2 responses by lymphocytes from cancer patients following in vivo treatment with interleukin-2.
Journal of biological response modifiers 1990;9(1):5-14.
1990: Bridges A J; Norback D; Fisch P; England D; Sondel P
T helper-cell leukemia/lymphoma: presentation as an acute immune-mediated illness.
Journal of clinical immunology 1990;10(1):61-70.
1990: Hank J A; Weil-Hillman G; Surfus J E; Sosman J A; Sondel P M
Addition of interleukin-2 in vitro augments detection of lymphokine-activated killer activity generated in vivo.
Cancer immunology, immunotherapy : CII 1990;31(1):53-9.
1990: Malkovska V; Sondel P M
Prospects for interleukin-2 therapy in hematologic malignant neoplasms.
Journal of the National Cancer Institute. Monographs 1990;(10):69-72.
1989: Chen B P; Lam V; Kraus E E; DeMars R; Sondel P M
Restriction of Epstein-Barr virus-specific cytotoxic T cells by HLA-A, -B, and -C molecules.
Human immunology 1989;26(2):137-47.
1989: Brown R R; Lee C M; Kohler P C; Hank J A; Storer B E; Sondel P M
Altered tryptophan and neopterin metabolism in cancer patients treated with recombinant interleukin 2.
Cancer research 1989;49(17):4941-4.
1989: Sosman J A; Oettel K R; Hank J A; Fisch P; Sondel P M
Specific recognition of human leukemic cells by allogeneic T cell lines.
Transplantation 1989;48(3):486-95.
1989: Fisch P; Weil-Hillman G; Uppenkamp M; Hank J A; Chen B P; Sosman J A; Bridges A; Colamonici O R; Sondel P M
Antigen-specific recognition of autologous leukemia cells and allogeneic class-I MHC antigens by IL-2-activated cytotoxic T cells from a patient with acute T-cell leukemia.
Blood 1989;74(1):343-53.
1989: Weil-Hillman G; Fisch P; Prieve A F; Sosman J A; Hank J A; Sondel P M
Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens.
Cancer research 1989;49(13):3680-8.
1989: Chen B P; Hank J A; Kraus E E; Sondel P M
Selective lysis of target cells by interleukin-2-expanded peripheral blood mononuclear leukocyte clones.
Cellular immunology 1989;118(2):458-69.
1989: Voss S D; Weil-Hillman G; Hank J A; Sosman J A; Sondel P M
The clinical immunobiology of interleukin-2: potential modified uses for improved cancer treatment.
Bulletin of the New York Academy of Medicine 1989;65(1):93-110.
1989: Carlin J M; Borden E C; Sondel P M; Byrne G I
Interferon-induced indoleamine 2,3-dioxygenase activity in human mononuclear phagocytes.
Journal of leukocyte biology 1989;45(1):29-34.
1989: Kohler P C; Hank J A; Moore K H; Storer B; Bechhofer R; Hong R; Sondel P M
Phase 1 clinical trial of recombinant interleukin-2: a comparison of bolus and continuous intravenous infusion.
Cancer investigation 1989;7(3):213-23.
1989: Voss S D; Hank J A; Nobis C A; Fisch P; Sosman J A; Sondel P M
Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation.
Cancer immunology, immunotherapy : CII 1989;29(4):261-9.
1989: Sondel P M; Hank J A
Prospects for clinical cancer treatment using interleukin-2.
Cancer investigation 1989;7(5):437-42.
1989: Sondel P M; Hank J A; Kohler P C; Sosman J A; Weil-Hillman G; Fisch P
The cellular immunotherapy of cancer: current and potential uses of interleukin-2.
Critical reviews in oncology/hematology 1989;9(2):125-47.
1989: Sondel P M; Hank J A; Kohler P C; Chen B P; Sosman J
"Lymphokine activated killing" as treatment for human cancer: clinical extrapolations from laboratory studies with interleukin-2 expanded leukocytes.
Progress in clinical and biological research 1989;288():151-60.
1988: Sosman J A; Kohler P C; Hank J A; Moore K H; Bechhofer R; Storer B; Sondel P M
Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule, and addition of indomethacin.
Journal of the National Cancer Institute 1988;80(18):1451-61.
1988: Weil-Hillman G; Hank J A; Rosenthal N S; Sondel P M
Transient decrease in IL-2-responsive lymphocytes 24 hours after initiation of continuous IL-2 infusion in cancer patients.
Journal of biological response modifiers 1988;7(5):424-37.
1988: Chen B P; DeMars R; Hank J A; Sondel P M
CD4+ proliferative T-cell clones reactive to autologous Epstein-Barr virus-transformed B cells (EBV-LCL) can be restricted by HLA class I molecules.
Cellular immunology 1988;115(2):363-72.
1988: Sondel P M; Kohler P C; Hank J A; Moore K H; Rosenthal N S; Sosman J A; Bechhofer R; Storer B
Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer.
Cancer research 1988;48(9):2561-7.
1988: Rosenthal N S; Hank J A; Kohler P C; Minkoff D Z; Moore K H; Bechhofer R; Hong R; Storer B; Sondel P M
The in vitro function of lymphocytes from 25 cancer patients receiving four to seven consecutive days of recombinant IL-2.
Journal of biological response modifiers 1988;7(2):123-39.
1988: Hank J A; Kohler P C; Weil-Hillman G; Rosenthal N; Moore K H; Storer B; Minkoff D; Bradshaw J; Bechhofer R; Sondel P M
In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2.
Cancer research 1988;48(7):1965-71.
1988: Sosman J A; Kohler P C; Hank J; Moore K H; Bechhofer R; Storer B; Sondel P M
Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity.
Journal of the National Cancer Institute 1988;80(1):60-3.
1988: Orchard P J; Moffet H L; Hafez G R; Sondel P M
Pseudomonas sepsis simulating acute promyelocytic leukemia.
The Pediatric infectious disease journal 1988;7(1):66-8.
1988: Burlingham W J; Grailer A; Sondel P M; Sollinger H W
Improved renal allograft survival following donor-specific transfusions. III. Kinetics of mixed lymphocyte culture responses before and after transplantation.
Transplantation 1988;45(1):127-32.
1988: Kohler P C; Hank J A; Minkoff D Z; Sondel P M
Clinical adoptive chemoimmunotherapy with allogeneic alloactivated HLA-haploidentical lymphocytes: controlled induction of graft-versus-host-reactions.
Cancer immunology, immunotherapy : CII 1988;26(1):74-82.
1987: Chen B P; Malkovsky M; Hank J A; Sondel P M
Nonrestricted cytotoxicity mediated by interleukin 2-expanded leukocytes is inhibited by anti-LFA-1 monoclonal antibodies (MoAb) but potentiated by anti-CD3 MoAb.
Cellular immunology 1987;110(2):282-93.
1987: Carlin J M; Borden E C; Sondel P M; Byrne G I
Biologic-response-modifier-induced indoleamine 2,3-dioxygenase activity in human peripheral blood mononuclear cell cultures.
Journal of immunology (Baltimore, Md. : 1950) 1987;139(7):2414-8.
1987: Moen R C; Horowitz S D; Sondel P M; Borcherding W R; Trigg M E; Billing R; Hong R
Immunologic reconstitution after haploidentical bone marrow transplantation for immune deficiency disorders: treatment of bone marrow cells with monoclonal antibody CT-2 and complement.
Blood 1987;70(3):664-9.
1987: Hong R; Horowitz S; Moen R; Trigg M; Sondel P; Billing R; Borcherding W; Johnson J P; Kanoff M; Bias W B
Thymus and B cell reconstitution in severe combined immunodeficiency after transplantation of monoclonal antibody depleted parental mismatched bone marrow.
Bone marrow transplantation 1987;1(4):405-9.
1987: Burlingham W J; Grailer A; Sparks-Mackety E M; Sondel P M; Sollinger H W
Kinetics of antidonor mixed lymphocyte culture responses in donor specific transfusions plus azathioprine-treated patients.
Transplantation proceedings 1987;19(1 Pt 3):2255-7.
1987: Burlingham W J; Grailer A; Sparks-Mackety E M; Sondel P M; Sollinger H W
Improved renal allograft survival following donor-specific transfusions. II. In vitro correlates of early (DST-type) rejection episodes.
Transplantation 1987;43(1):41-6.
1987: Sondel P M; Hank J A; Rosenthal N; Moore K H; Hong R; Storer B; Kohler P C
Clinical testing of IL-2: in vivo administration of IL-2 induces IL-2 dependent non-MHC-restricted cytotoxicity (NRC).
Progress in clinical and biological research 1987;244():173-84.
1987: Kohler P C; Hank J A; Moore K H; Storer B; Bechhofer R; Sondel P M
Phase 1 clinical evaluation of recombinant interleukin-2.
Progress in clinical and biological research 1987;244():161-72.
1987: Orchard P J; Dickerman J D; Mathews C H; Frierdich S; Hong R; Trigg M E; Shahidi N T; Finlay J L; Sondel P M
Haploidentical bone marrow transplantation for osteopetrosis.
The American journal of pediatric hematology/oncology 1987;9(4):335-40.
1987: Sondel P M; Hank J A; Chen B P; Mandell R; Sosman J; Kohler P C
Overview: cellular immunotherapy of cancer.
Progress in clinical and biological research 1987;244():3-14.
1986: Kohler P C; Erickson C; Finlay J L; Trigg M E; Edwards B; Hong R; Hank J A; Billing R; Bozdech M; Sondel P M
In vitro analysis of donor bone marrow following monoclonal antibody treatment for the prevention of acute graft versus host disease.
Cancer research 1986;46(10):5413-8.
1986: Sondel P M; Hank J A; Kohler P C; Chen B P; Minkoff D Z; Molenda J A
Destruction of autologous human lymphocytes by interleukin 2-activated cytotoxic cells.
Journal of immunology (Baltimore, Md. : 1950) 1986;137(2):502-11.
1986: Sondel P M; Hank J A; Trigg M E; Kohler P C; Finlay J L; Blank J; Meisner L; Borcherding W; Hong R; Steeves R
Transplantation of HLA-haploidentical T-cell-depleted marrow for leukemia: autologous marrow recovery with specific immune sensitization to donor antigens.
Experimental hematology 1986;14(4):278-86.
1986: Trigg M E; Peterson A; Erickson C; Bozdech M; Billing R; Sondel P; Finlay J; Surfus J; Stuiber M; Hong R
Depletion of T cells from bone marrow for allogeneic transplantation: method for treatment of bone marrow in bulk.
Experimental hematology 1986;14(1):21-6.
1986: Finlay J L; Ganick D J; Shahidi N; Borcherding W; Hong R; Sondel P
T-lymphoblasts with erythropoietic helper function in acute T-cell leukemia.
Pediatric hematology and oncology 1986;3(3):273-82.
1985: Trigg M E; Sondel P M; Billing R; Finlay J L; Peterson A; Hong R; Frierdich S; Shahidi N
Mismatched bone marrow transplantation in children with hematologic malignancy using T lymphocyte depleted bone marrow.
Journal of biological response modifiers 1985;4(6):602-12.
1985: Bozdech M J; Sondel P M; Trigg M E; Longo W; Kohler P C; Flynn B; Billing R; Anderson S A; Hank J A; Hong R
Transplantation of HLA-haploidentical T-cell-depleted marrow for leukemia: addition of cytosine arabinoside to the pretransplant conditioning prevents rejection.
Experimental hematology 1985;13(11):1201-10.
1985: Sondel P M; Hank J A; Molenda J; Blank J; Borcherding W; Longo W; Trigg M E; Hong R; Bozdech M J
Relapse of host leukemic lymphoblasts following engraftment by an HLA-mismatched marrow transplant: mechanisms of escape from the "graft versus leukemia" effect.
Experimental hematology 1985;13(8):782-90.
1985: Trigg M E; Billing R; Sondel P M; Exten R; Hong R; Bozdech M J; Horowitz S D; Finlay J L; Moen R; Longo W
Clinical trial depleting T lymphocytes from donor marrow for matched and mismatched allogeneic bone marrow transplants.
Cancer treatment reports 1985;69(4):377-86.
1985: Kohler P C; Hank J A; Exten R; Minkoff D Z; Wilson D G; Sondel P M
Clinical response of a patient with diffuse histiocytic lymphoma to adoptive chemoimmunotherapy using cyclophosphamide and alloactivated haploidentical lymphocytes. A case report and phase I trial.
Cancer 1985;55(3):552-60.
1984: Trigg M E; Billing R; Sondel P M; Dickerman J D; Erickson C; Finlay J L; Bozdech M; Hong R; Padilla-Nash H; Terasaki P
Depletion of T cells from human bone marrow with monoclonal antibody CT-2 and complement.
Journal of biological response modifiers 1984;3(4):406-12.
1984: Sondel P M; Kohler P C; Hank J A; Bozdech M J; Lieberman L M; Hong R; Albertini R; Exten R E
The in vivo distribution of indium-111 labeled in vitro alloactivated syngeneic lymphocytes in a patient with relapsed acute myelomonocytic leukemia: implications for adoptive chemoimmunotherapy.
Leukemia research 1984;8(5):893-903.
1983: Sondel P M; Hank J A; Wendel T; Flynn B; Bozdech M J
HLA identical leukemia cells and T cell growth factor activate cytotoxic T cell recognition of minor locus histocompatibility antigens in vitro.
The Journal of clinical investigation 1983;71(6):1779-86.
1983: Ganick D J; Sondel P M; Gilbert E F; Borcherding W
Leukemia presenting as central nervous disease without bone marrow involvement.
Medical and pediatric oncology 1983;11(4):229-32.
1981: Sondel P M; Borcherding W; Shahidi N T; Ganick D J; Schultz J C; Hong R
Recategorizing childhood acute lymphoblastic leukemia with monoclonal antibodies to human T cells.
Blood 1981;57(6):1135-7.

Sign-in to see more